Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Switzerland's Shield Therapeutics Raises $12M To Conduct Phase III Trials On Oral Iron Deficiency Product

This article was originally published in The Pink Sheet Daily

Executive Summary

Oral iron deficiency therapy to advance into Phase III this year on the back of $12 million fund raising for Swiss minnow, Shield Therapeutics.

You may also be interested in...



Shield To File ST10 Oral Iron-Deficiency Drug After Strong Phase III Data

Shield Therapeutics will use robust Phase III data for its oral iron-deficiency therapy ST10 to seek marketing approval in Europe in the second half of 2014 for iron-deficiency anemia in inflammatory bowel disease, and then a subsequent NDA submission in the U.S. for treating iron-deficiency anemia in pre-dialysis patients with chronic kidney disease.

Financings Of The Fortnight Sees A Hot Market For Health Care IPOs ... In China

Plus news on recent financings by Array Biopharma, Delenex Therapeutics, Naurex and Fate Therapeutics.

Switzerland's Anergis Closes Series A Funding For Allergy Vaccine Trial

Anergis raises CHF 18 million from European venture funds to support Phase II study of fast-acting approach to allergy desensitization.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel